Alba®: A Breakthrough Solution For Biologics
Medicines are particularly sensitive to all the components of the primary packaging they are in contact with, which might impair the compatibility between drug products and the container closure system. Discover a solution capable of addressing the development of sensitive biologics, such as highly concentrated drugs prone to silicone aggression and ophthalmic drugs.
De-risking the development of sensitive drugs.
Alba® EZ-fill® syringes represent the best-in-class solution for biologics and ophthalmic applications addressing the key requirements of protein-based drugs, and minimizing adsorption, aggregation and inorganic extractable interaction.
All Alba® EZ-fill® products have an internal coating, based on standard silicone oil, which is cross-linked to form a chemical bond with the glass surface. It ensures that particle levels - caused by silicone migration during container storage - are significantly lower than ones using standard siliconization technologies. Moreover, the internal treatment offers superior gliding performance, reducing the risk of functional issues when combined with auto-injectors.
Due to the excellent properties of the layer, Alba® platform mitigates packaging-related risks and enhances drug-interaction stability.
Available Formats:
Benefits:
- Particle reduction - Minimized subvisible particles versus conventional sprayed-on siliconized containers to alleviate potential drug-silicone interaction.
- Optimized break-loose and glide performance - Silicone lubricant layer integrity, optimized to withstand challenging formulations and aggressive conditions, helps conserve gliding performances throughout the drug shelf-life.
- Reduction risk of stalling and injection time variation - The low silicone-drug interaction helps to maintain the injection time and dose delivery with an auto-injector.
- Inorganic extractable mitigation - A barrier between the drug and the glass reduces the amount of inorganic extractables.
- Time stability - Alba® inner coating does not undergo critical variations after contact with the placebo solution over a period of 6 months (tested @40°C/75%RH).
Preferred Market Choice:
- Protein-based therapeutics
- Ophthalmic applications